Thus, because BATF is both a driver of effector differentiation and a suppressor of memory, its transcriptional circuits may be activated to generate more effector-like CD8+ T cells, or repressed to generate more memory-like CD8+ T cells, ultimately improving anti-tumour efficacy. The gene discussed is CD8A; the disease is neoplasm.